Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$865.00 USD

865.00
3,343,664

+15.01 (1.77%)

Updated Jun 10, 2024 04:01 PM ET

After-Market: $875.00 +10.00 (1.16%) 5:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 248)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

What's in the Cards for IDEX (IEX) this Earnings Season?

IDEX Corporation (IEX) is scheduled to report first-quarter 2017 results after the closing bell on Apr 19.

    Tirthankar Chakraborty headshot

    Profit from These 5 Sturdy Stocks as Fear Grips Markets

    Wall Street's fear gauge is breaking out higher as geopolitical risks heat up after the U.S. opted for 'Mother of All Bombs'.

      J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?

      We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.

        What's in the Cards for Omnicom (OMC) this Earnings Season?

        Omnicom Group Inc. (OMC) is scheduled to report first-quarter 2017 results before the opening bell on Apr 18.

          ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study

          Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).

            Merck's Bid to Add Cardiovascular Data on Januvia Label Fails

            Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.

              Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549

              We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.

                Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC

                Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.

                  AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA

                  AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.

                    5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now

                    Lily carries a Zacks Rank #2 (Buy).

                      Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC

                      Novartis AG (NVS) recently announced that the European Commission has approved Tafinlar in combination with Mekinist for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).

                        United Therapeutics Tanks, Remodulin Pump Launch Delayed

                        United Therapeutics Corporation (UTHR) shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for delivering Remodulin

                          Arpita Dutt headshot

                          4 FDA Decisions to Watch Out for in Apr 2017

                          Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.

                            Why Equal Weighted Mutual Funds Scoring Over Index Funds

                            Investors interested in maintaining a diversified portfolio might consider investing in equal-weight funds.

                              AstraZeneca Stock Rising in '17: What's Working in its Favor?

                              Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.

                                Merck Closes Acquisition of Controlling Stake in Vallee S.A

                                Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.

                                  Novartis' Acute Heart Failure Drug Fails in Late-Stage Study

                                  Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).

                                    Lilly's Breast Cancer Combo Drug Phase III Results Positive

                                    Eli Lilly and Company (LLY) recently announced that a phase III combination study evaluating its pipeline candidate abemaciclib in advanced breast cancer, met the primary endpoint of progression-free survival (PFS).

                                      Novartis (NVS) Announces Positive Data on Heart Failure Drug

                                      Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.

                                        What are Sanofi's (SNY) Strengths and Challenges in 2017?

                                        We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.

                                          Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays

                                          We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.

                                            Arpita Dutt headshot

                                            How Incyte Stock Became a Bull Market Star for Biotech Investors

                                            Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.

                                              Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA

                                              Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.

                                                Sweta Killa headshot

                                                Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs

                                                President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.

                                                  Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara

                                                  Eli Lilly and Company (LLY) announced superior efficacy in a head-to-head study evaluating its marketed drug, Taltz (ixekizumab) versus with Johnson & Johnson???s Stelara (ustekinumab) in patients with moderate-to-severe plaque.